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Abstract
Genetic studies revealed that the ablation of insulin/IGF-1 signaling in the pancreas causes diabetes. FoxO1 is a downstream
transcription factor of insulin/IGF-1 signaling. We previously reported that FoxO1 haploinsufficiency restored b cell mass and
rescued diabetes in IRS2 knockout mice. However, it is still unclear whether FoxO1 dysregulation in the pancreas could be
the cause of diabetes. To test this hypothesis, we generated transgenic mice overexpressing constitutively active FoxO1
specifically in the pancreas (TG). TG mice had impaired glucose tolerance and some of them indeed developed diabetes due
to the reduction of b cell mass, which is associated with decreased Pdx1 and MafA in b cells. We also observed increased
proliferation of pancreatic duct epithelial cells in TG mice and some mice developed a polycystic pancreas as they aged.
Furthermore, TG mice exhibited islet hypervascularities due to increased VEGF-A expression in b cells. We found FoxO1
binds to the VEGF-A promoter and regulates VEGF-A transcription in b cells. We propose that dysregulation of FoxO1
activity in the pancreas could account for the development of diabetes and pancreatic cysts.
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Introduction
Pancreatic b cells secrete insulin to maintain plasma glucose
levels at an appropriate physiological range. Relative defects in b
cell functions cause type 2 diabetes. Recent genetic studies
revealed that insulin/IGF-1 signaling plays a role in b cell growth
and function [1,2]. The insulin/IGF-1 signaling pathway in b cells
is mainly mediated by insulin receptor substrate-2 (IRS-2), PI3-
kinase, 3-phosphoinositide-dependent protein kinase 1 (Pdk-1),
and Akt. Mice lacking IRS-2 develop diabetes due to reduced b
cell mass and peripheral insulin resistance [3,4]. Mice lacking Pdk-
1, specifically in pancreatic b cells, develop progressive hypergly-
cemia ensued from a loss of islet mass [5]. Transgenic mice
overexpressing the active form of Akt1 under the rat insulin
promoter had increased numbers of b cells and high plasma
insulin levels, leading to improved glucose tolerance and resistance
to diabetes [6].
The FoxO (Forkhead box-containing protein, O-subfamily)
transcription factors are downstream effectors of insulin/IGF-1
signaling. Insulin/IGF-1 activates PI3-kinase/Akt pathway. Acti-
vated Akt translocates to the nucleus and phosphorylates FoxO1,
which leads from nucleus to cytoplasm translocation of FoxO1.
Because FoxO1 is inactive in the cytoplasm, insulin/IGF-1
pathway essentially inhibits FoxO1 transcriptional activity
[7,8,9]. The FoxO family contains four isoforms, FoxO1, FoxO3a,
FoxO4, and FoxO6; FoxO1 is the most abundant isoform in
pancreatic b cells [10]. Haploinsufficiency for FoxO1 resulted in
an increase of b cells and rescued both IRS-2 knockout mice and
Pdk-1 knockout mice from diabetes via restoration of Pdx1
expression in b cells [5,10]. Pdx1 is a key transcription factor for b
cell growth and function [11,12]. In vitro assays in b cell cultures
revealed that FoxO1 inhibits Pdx1 transcription by competing
with FoxA2 for a common binding site in the Pdx1 promoter [10].
FoxO1 and Pdx1 have been reported to show mutually exclusive
nuclear localization [5,13,14]. Interestingly, the expression pattern
of FoxO1 during mouse pancreas development closely parallels
Pdx1 expression, i.e. widely expresses at E14.5, becomes restricted
to endocrine cells at E17.5, and is confined to b cells postnatally;
the difference is that FoxO1 is cytoplasmic and Pdx1 nuclear [15].
On the other hand, we also reported that FoxO1 controls
myogenic differentiation cooperatively with Notch signaling [16].
Notch signaling is critical for pancreatic cell and myogenic
differentiation [17,18]. Thus, the accumulated evidence suggests
FoxO1 dysregulation in the pancreas could be the cause of
diabetes or pancreatic disease.
To test this hypothesis in vivo, we generated pancreas specific
FoxO1 transgenic mice (TG) [15]. TG mice constitutively express
the nuclear FoxO1 mutant (FoxO1-ADA) [19] under the Pdx1
promoter [17], and have transgene expression in .90% of
pancreatic cells [15]. TG mice have reduced exocrine acinar cells
and abnormal composition of islet cells during pancreas
development [15]. However, glucose metabolism and pancreatic
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Therefore, in the present study, we investigated metabolism
parameters and pancreas morphology in adult TG mice. We
showed that dysregulation of FoxO1 in pancreas causes diabetes,
polycystic pancreas and islet hypervascularization.
Materials and Methods
Animal generation and analytical procedures
Pdx-FoxO1ADA transgenic mice generated by a transgene
encoding the 4.5 kb Pdx1 promoter [17] followed by the cDNA of
FLAG-tagged FoxO1ADA [19] were described previously [15].
PCR genotyping was carried out with the following primers: 59-
GCT TAG AGC AGA GAT GTT CTC ACA TT-39,5 9-CCA
GAG TCT TTG TAT CAG GCA AAT AA-39, and 59-CAA
GTC CAT TAA TTC AGC ACA TTG A-39. Individually caged
mice were fed either normal chow or high fat high sucrose diet
(HFHSD) beginning at 4 weeks of age for an 8-week period. In the
HFHSD, 55% of calories were from fat, 28% from carbohydrates,
and 17% from protein (Oriental Yeast Co., Ltd). We purchased
male db/db mice from CLEA Japan (Tokyo, Japan). All animal
care and experimental procedures were approved by the
Institutional Animal Care and Use Committee at Gunma
University (#06-54 and #08-01). All animal experimentation
described in the manuscript was conducted in accordance with
accepted standards of humane animal care, as outlined in the
ethical guidelines. We measured blood glucose levels with a
glucometer (Sanwa Kagaku, Nagoya), and plasma insulin levels by
ELISA (Shibayagi) and plasma glucagon levels by RIA (Millipore).
We carried out all assays in duplicate. Each value represents the
mean of two independent determinations. For the glucose
tolerance test, we subjected mice to an overnight fast followed
by an intraperitoneal glucose injection (1.2 g/kg), and obtained
blood samples 0, 15, 30, 60, and 120 min after the injection. For
insulin tolerance test, we injected human insulin (0.75 U/kg)
intraperitoneally and obtained blood samples 0, 15, 30 and 60 min
after the injection.
Antibodies and immunohistochemistry
We used the following antibodies: anti-Pdx1 (a kind gift from Dr
Kaneto at Osaka Univ), anti-insulin (DAKO), anti-glucagon
(Sigma), anti-FLAG (Sigma), anti-Ki67 (Lab Vision), anti-MafA
(Bethyl), anti-PECAM1 (Endogen), and anti-VEGF-A (Fitzgerald).
We used fluorescent-conjugated DBA (0.05 mg/ml, Vector
Laboratories) for duct epithelial cell staining. We performed
immunostaining using 5 mm-thick paraffin sections and, in some
experiments, antigen retrieval, as described previously [10]. We
visualized immune complexes with FITC- or CY3-conjugated
secondary antibodies. To quantify the % area of b cells or a cells
vs. pancreas, we measured the area of insulin staining or glucagon
staining using BZ-8100 (Keyence) and NIS-Elements (Nikon). We
scored at least 10 sections for each mouse and six mice for each
genotype.
Islet isolation from mice
Islets were purified from mice by collagenase digestion followed
by centrifugation over a Histopaque gradient, as described
previously [20].
Cell culture and adenoviral vectors
bTC3 and MIN6 cells were kindly provided from D. Accili
(Columbia University) [10]. We previously described adenoviral
vectors encoding FoxO1-ADA or GFP [19]. We infected the cells
with adenovirus 24 hrs prior to isolating mRNA or to preparing
samples for luciferase assays.
Luciferase assays and chromatin immunoprecipitation
(ChIP) aasays
We performed luciferase assays as previously described [10]. We
generated a VEGF-A luciferase vector containing the promoter
region (21217 to +180) of mouse VEGF-A (pGL3-VEGF-A). We
performed ChIP assays in MIN6 cells following previously
described methods [21]. We used anti-FoxO1 (Santa-Cruz, H-
128), anti-FoxO3a (Santa-Cruz, H-144) antibodies and the
following primers: FHRE5; 59-CTT CCC AGA GGA TCC
CAT TCA CCC C-39 and FHRE3; 59-GCC GAG CGC CCC
CTA GTG AC-39 (corresponding to 2805 to 2781 and 2525 to
2506 of the mouse VEGF-A gene, respectively). As control
primers, we used Cont5; 59-TCC CAG TGT GTT CCT GAG
CCC A-39 and Cont3; 59-TCT CGC GAC AGA GCT CCG CT-
39 (corresponding to 2220 to 2199 and +68 to +87 of the mouse
VEGF-A gene, respectively).
mRNA isolation and real-time RT-PCR
We extracted mRNA from mouse islets, b TC3, or MIN6 cells
using the Micro Fast Track 2.0 kit (Invitrogen). We performed
real-time RT-PCR using the ImProm-II
TM Reverse Transcription
System (Promega) and LightCycler System (Roche). Primer
sequences used for real-time PCR are as follows, for PECAM1;
59- AGG GGA CCA GCT GCA CAT TAG G-39 and 59-AGG
CCG CTT CTC TTG ACC ACT T-39, for VEGF-A; 59- TGT
ACC TCC ACC ATG CCA AGT-39 and 59- TGG AAG ATG
TCC ACC AGG GT-39, for Pdx1; 59- ACC ATG AAC AGT
GAG GAG CA -39 and 59- TCC TCT TGT TTT CCT CGG
GT-39, for MafA; 59- AGG CCT TCC GGG GTC AGA G -39
and 59- TGG AGC TGG CAC TTC TCG CT-39. We carried out
each reaction in triplicate, using a standard curve with the relevant
cDNA for each primer set.
Statistical analyses
We carried out descriptive statistics and analysis of variance
(ANOVA) followed by Fisher’s test using the Statview software
(Abacus concepts).
Results
Hyperglycemia and impaired glucose tolerance in TG
mice
We generated transgenic mice overexpressing constitutively
active FoxO1 specifically in the pancreas, using a transgene
encoding a 4.5 kb Pdx1 promoter [17] followed by the cDNA of a
constitutively nuclear mutant of FoxO1 (FoxO1-ADA) [19]. In this
system, the Pdx1 promoter could be inhibited by its FoxO1
transgene product, however we confirmed that more than 90% of
pancreatic cells expressed FoxO1-ADA in these mice [15]. One
possibility is that because Pdx1 promoter is in fact inhibited by
FoxO1-ADA, the level of transgene expression is only twofold
higher than endogenous gene [15]. Another possibility is that the
inhibition of endogenous Pdx1 expression is not necessarily a result
of a direct effect of FoxO1, but it can be secondary to increased
mRNA degradation or to promoter elements located outside the
region we used to make transgenic mouse. Though Pdx1 is known
to express in the brain as well as pancreas, FoxO1-ADA
expression was observed neither in the brain nor in the other
organs except pancreas of TG mice (data not shown). Although we
already reported the phenotype of pancreatic morphology during
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adult TG mice, such as metabolic parameters and pancreas
architecture remained unsolved. Therefore, we first examined
blood glucose levels at 8 weeks of age from both fasted and ad-lib
fed mice. As seen in Fig. 1A, around 30% of male TG mice
showed hyperglycemia in both fasted and fed conditions.
Interestingly, none of the female TG mice developed hyperglyce-
mia. Plasma insulin secretion in response to intraperitoneal glucose
injection was blunted in male diabetic TG mice, indicating that
hyperglycemia was caused by impaired insulin secretion in these
mice (Fig. 1B). However, around 70% of male and all female TG
mice showed almost normal blood glucose levels (Fig. 1A);
therefore, we next performed intraperitoneal glucose tolerance
tests (IPGTT) in the TG mice that had normal blood glucose levels
in fasted and fed states at 12 weeks of age. IPGTT revealed that
male, but not female, TG mice had impaired glucose tolerance;
although, statistical significance was seen only at 30 and 60 min
(Fig. 1C). There was no difference in the average body weight
Figure 1. Hyperglycemia and impaired glucose tolerance in TG mice. (A) Blood glucose levels (mg/dl) in fasted and ad-lib fed TG mice and
their control littermates at 8 weeks of age. (B) Plasma insulin levels (ng/ml) before and 15 min after glucose (1.2 g/kg) intraperitoneal injection. (C)
Intraperitoneal glucose tolerance tests (IPGTT) in male (left) and female (right) TG mice that had normal blood glucose levels in fasted and fed states
at 8 weeks of age. (D) Insulin tolerance test (ITT) in male (left) and female (right) TG and control mice at 12 weeks of age. (E) Plasma insulin (left) and
glucagon (right) levels in fasted and fed conditions in TG and control mice at 12 weeks of age. (F) The size-matched islets were isolated from male TG
and control mice at 12 weeks of age, and glucose-stimulated insulin secretion levels were measured in those islets. The data were normalized by DNA
content in those islets (G and H) TG mice that had normal blood glucose levels at 4 weeks of age and their control littermates were fed a HFHSD for 8
weeks further, then, fasted blood glucose levels were measured (G) and IPGTT performed (H) in both male (left) and female (right) mice. In each
experiment (A–H), at least six male or female mice for each genotype were analyzed. In the line graphs, closed triangle indicates TG mice and open
circle indicates control mice. Data represent mean 6 SEM. * or ** indicates P,0.05 or P,0.01 by ANOVA.
doi:10.1371/journal.pone.0032249.g001
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24.561.4 g). To rule out the possibility of insulin resistance in
TG mice, we performed insulin tolerance test (ITT). There was no
difference in ITT results between TG and control mice in both
male and female (Fig. 1D), indicating that impaired glucose
tolerance was not caused by the peripheral insulin resistance in
TG mice. We also measured plasma insulin and glucagon levels in
male TG mice. As shown in Fig. 1E, plasma insulin levels were
significantly lower in TG than control mice in both fasted and fed
conditions, which is consistent with the impaired glucose
responsive insulin secretion in male TG mice (Fig. 1B). Interest-
ingly, plasma glucagon levels were higher in TG than control mice
in the fed conditions (Fig. 1E). Although the mechanism is unclear,
enhanced glucagon secretion may deteriorate the glucose
intolerance in TG mice. To further evaluate the impaired insulin
secretion in TG mice, we isolated islets from TG and control mice
and performed glucose stimulated insulin secretion (GSIS) assays.
Because small islets in TG mice have lower b cell/a cell ratio than
in the control mice (as shown in Fig. 2A), we used the size-matched
large islets between TG and control mice, in which b cell mass
should be comparable. Consistent with the data of plasma insulin
levels, TG islets have decreased glucose-responsive insulin
secretion (Fig. 1F). We next started feeding a high fat high sucrose
diet (HFHSD) to the TG mice whose blood glucose levels were
normal, at least until 4 weeks of age. After HFHSD feeding for 8
weeks, we measured blood glucose levels and found the average
blood glucose level in male TG mice was significantly higher than
in control mice, and these mice developed overt diabetes (Fig. 1G).
Figure 2. Reduced b cell mass and decreased expression of Pdx1 and MafA in TG mice. (A) Double immunohistochemistry with anti-insulin
and anti-glucagon antibodies were conducted in pancreatic sections from TG and control mice. Representative images of low (upper panels) and
high (lower panels) magnifications are shown. (B) The % area of b cells (left panel) or a cells (right panel) vs. whole pancreatic area was scored as
described in Methods. (C and D) Double immunostaining of insulin with Pdx1 (C) or MafA (D) were conducted in pancreatic sections from TG and
control mice. Arrows indicate individual cysts in TG pancreas. Representative images are shown. (E) Islets were isolated from TG and control mice and
used for analyses by real time RT-PCR. In each experiment (A–E), at least six male and six female mice of each genotype and ten sections per mouse
were analyzed. All the results were normalized using GAPDH. There was no significant difference between male and female mice. Data represent
mean 6 SEM. An asterisk indicates P,0.05 by ANOVA.
doi:10.1371/journal.pone.0032249.g002
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exhibited significantly impaired glucose tolerance under a HFHSD
(Fig. 1H).
Reduced b cell mass and decreased expression levels of
Pdx1 and MafA in TG mice
We previously showed FoxO1 inhibits b cell proliferation
through suppression of Pdx1 transcription in b cells [10];
therefore, we expected b cell mass should be decreased in TG
mice. Double staining of insulin and glucagon in pancreatic
sections revealed the b cell area decreased while the a cell area was
relatively increased in TG mice compared to control mice
(Fig. 2A). We quantified the area of b cells or a cells as a % of
the whole pancreatic area, showing that the b cell area was
significantly decreased, whereas a cell area tended to be increased
in TG mice compared to control mice (Fig. 2B). Although
abnormalities in glucose metabolism were milder in female than
male TG mice, we couldn’t see any difference in pancreas
morphology between males and females. We next investigated
Pdx1 expression in the pancreas using immunohistochemistry with
anti-Pdx1 antibody. For this investigation, we selected the TG
islets which contain the similar number of b cells to the control
islets. In control mice, Pdx1 is expressed in almost all insulin-
positive b cells, whereas only a few insulin-positive b cells express
Pdx1 in TG mice (Fig. 2C). These results are consistent with our
previous hypothesis that FoxO1 inhibits Pdx1 transcription and,
thereby, inhibits b cell proliferation [10]. Although we have also
reported that FoxO1 is a positive regulator for MafA transcription
[21], MafA expression was decreased in b cells of TG mice
(Fig. 2D). To quantify these results, we isolated islets from TG and
control mice and performed real time RT-PCR analysis.
Consistent with the results of immunohistochemistry, both Pdx1
and MafA expression levels were significantly decreased in TG
mice (Fig. 2E). However, given that the % of b cells in the islets is
decreased in TG mice and that Pdx1 and MafA are exclusively
expressed in b cells, these quantitative data may overestimate the
reduction of Pdx1 and MafA expression. Nonetheless, these
combined results of immunohistochemistry and real time RT-
PCR indicated that Pdx1 and MafA, two critical transcription
factors for b cell proliferation, are decreased, which may be the
cause of decreased b cell mass in TG mice.
Enhanced proliferation of pancreatic duct epithelial cells
and development of polycystic pancreas in TG mice
As we previously reported [15], the TG pancreas contained
numerous duct-like structures. Lectin-DBA staining, a marker for
duct epithelial cells, revealed that these structures were indeed
pancreatic ducts (Fig. 3A). More interestingly, most of the Lectin-
DBA positive cells in the TG pancreas were Ki67 positive,
indicating that duct cells were vigorously proliferating in these mice
(Fig. 3A, right panel). The turnover of pancreatic duct epithelial
cells is essentially very slow, as seen in pancreatic sections from
control mice where no Ki67 positive cells were detected in the duct
(Fig. 3A, left panel). As a consequence of vigorous and continuous
proliferation of pancreatic duct epithelial cells, we expected TG
mice might develop pancreatic cysts in their old age due to the
formation of enlarged pancreatic ducts. As expected, multiple cysts
formed in the pancreas of 12 month old TG mice (Fig. 3B).
According to the cytopathological malignant criteria, pancreatic
cysts in TG micecontained no malignant cells,indicatingthesecysts
were not cancerous (Fig. 3C). Furthermore, pancreatic cysts were
formed by a monolayer of Lectin-DBA positive duct epithelial cells,
most of which were Ki67 positive (Fig. 3D).
Islet hypervascularities in TG mice are associated with
increased VEGF-A expression in b cells
It appeared islet capillaries were increased in TG mice based on
observations from hematoxylin and eosin staining of pancreatic
sections (Fig. 4A, top panels). We previously reported that
PECAM1 (a marker for vascular endothelial cells) positive cells
were increased in TG islets [15], and that was reconfirmed in the
present study (Fig. 4A, middle panels). Interestingly, the
immunoreactivity with anti-vascular endothelial growth factor-A
(VEGF-A) was increased in islets of TG mice compared to control
mice (Fig. 4A, bottom panels). We showed VEGF-A positive cells
Figure 3. Enhanced proliferation of pancreatic duct epithelial
cells and development of polycystic pancreas in TG mice. (A)
Immunohistochemistry with anti-Ki67 antibody (red) along with Lectin-
DBA (green) was conducted in pancreatic sections from 2 month old TG
and control mice. Representative results are shown. (B) Photographs of
the pancreas in 12 month old TG and control mice. Representative
pictures are shown. (C) Hematoxylin and eosin (HE) staining (left panel
indicates640 magnification and right6400) in pancreatic sections from
12 month old TG mice. Representative images are shown. (D)
Immunohistochemistry with anti-Ki67 antibody (red) along with
Lectin-DBA (green) was conducted in pancreatic sections from 12
month old TG mice. Representative images of pancreatic cysts are
shown. Arrow indicates Ki67 positive cells.
doi:10.1371/journal.pone.0032249.g003
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insulin or glucagon (Fig. 5). To quantify these results, we
performed real-time RT-PCR and densitometry analysis, and
showed that both PECAM1 and VEGF-A were significantly
increased in TG islets compared to control islets (Fig. 4B and 5B),
despite that the number of b cells were decreased in TG islets
Figure 4. Islet vasculature and VEGF-A expression in b cells are increased in TG mice via FoxO1 regulation of VEGF-A transcription.
(A) Hematoxylin and eosin (HE) staining and immunohistochemistry with anti-PECAM1 or anti-VEGF-A antibodies in pancreatic sections from 2 month
old TG and control mice. Representative images are shown. (B) Islets were isolated from TG and control mice and used for analyses by real-time RT-
PCR to quantify PECAM1 and VEGF-A mRNA levels. In each experiment (A and B), six male and six female mice were analyzed for each genotype.
There was no difference between male and female mice. Data represent the mean 6 SEM fold-increase relative to control mice. An asterisk indicates
P,0.05 by ANOVA. (C) b TC3 or MIN6 cells were infected with adenoviruses expressing FoxO1 ADA or GFP at indicated MOI, 24 hrs later mRNA was
isolated from the cells and used for real-time RT-PCR to quantify VEGF-A mRNA levels. The results of (B) and (C) were normalized using GAPDH. (D)
VEGF-A promoter driven luciferase activities were measured in MIN6 cells infected with adenoviruses expressing FoxO1 ADA or GFP at indicated MOI.
For (C) and (D), data represent the mean 6 SEM fold-increase relative to GFP infection. An asterisk indicates P,0.05 by ANOVA. (E) The promoter
region of the mouse VEGF-A gene. Square indicates the location of the forkhead responsive element (FHRE). For ChIP assays, a primer set spanning
three FHREs and control primers were used. An arrow indicates the initiation site of RNA synthesis and is designated +1. (F) ChIP assays of the VEGF-A
promoter are shown. We performed ChIP assays in MIN6 cells with indicated antisera. NRS indicates normal rabbit serum used as a control antisera.
The crosslinked DNA was amplified by PCR using FHRE and Cont primers. Input represents DNA extracted from chromatin prior to
immunoprecipitation. We used input DNA with 1:100 dilution.
doi:10.1371/journal.pone.0032249.g004
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constitutively active FoxO1 increased VEGF-A expression in b
cells and, thereby, increased the number of capillaries in islets.
FoxO1 regulates VEGF-A transcription in b cells
We next investigated the mechanism by which FoxO1 regulates
VEGF-A expression in b cells. First we tested whether overex-
pression of constitutively active FoxO1 (FoxO1-ADA) increases
VEGF-A expression in cell culture. We infected b TC3 cells or
MIN6 cells, two conventional cell lines for pancreatic b cells, with
adenovirus expressing FoxO1-ADA. Real-time RT-PCR analyses
revealed that VEGF-A mRNA levels were significantly increased
by FoxO1-ADA in a dose dependent manner in both cell lines
(Fig. 4C). We then constructed a luciferase vector, which
contained a mouse VEGF-A promoter (21217 to +180) and
measured the promoter activities. As we expected, the adenovirus
mediated expression of FoxO1-ADA increased VEGF-A promoter
activities in a dose dependent manner in MIN6 cells (Fig. 4D).
Mouse VEGF-A promoter region contains three forkhead
responsive elements (FHREs) as indicated in Fig.4E. By using
the primers spanning these three FHREs, we performed ChIP
assays, which clearly demonstrated that FoxO1 binds to the
VEGF-A promoter in intact chromatin (Fig. 4F). Because FoxO3a,
another isoform of FoxO family, is also expressed in adult
pancreas [10,22], we tested whether FoxO3a also binds to the
VEGF-A promoter in b cells. However, ChIP assays indicated no
binding of FoxO3a to the VEGF-A promoter region including
three forkhead responsive elements (Fig. 4F). These results indicate
that FoxO1 specifically regulates VEGF-A transcription in b cells.
Islet vascularity and VEGF-A expression in diabetic model
mice
Genetic studies have revealed that islet vascular formation,
which is regulated by VEGF-A in b cells, is important for the
control of blood glucose levels [23,24,25]. However, the
physiological relevance between VEGF-A/islet vascularity and
compensatory b cell hyperplasia against peripheral insulin
resistance is still unclear. We investigated the expression levels of
PECAM1 and VEGF-A in islets of two animal models for insulin
resistance, HFHSD fed mice and db/db mice. Interestingly, both
PECAM1 and VEGF-A expression in islets were increased in
HFHSD fed mice; however, expression was unchanged or tended
to be decreased in db/db mice (Fig. 6A and 6B). Although both
animal models are known to exhibit compensatory b cell
Figure 5. Enhanced VEGF-A expression in b cells but not a cells in TG mice. (A) Double immunostaining of VEGF-A with insulin or glucagon
in pancreatic sections from TG mice and control mice. Enhanced VEGF-A staining (red) in TG mice is completely merged with insulin staining (green
to yellow) but not with glucagon staining (green). (B) Quantitative analysis of VEGF-A staining levels in the islets of TG and control mice. We measured
the staining levels of VEGF-A per unit area by using NIS-Elements (Nikon) and Image-J (NIH). Six mice were analyzed for each genotype and
representative images are shown.
doi:10.1371/journal.pone.0032249.g005
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normal (121620 mg/dl); whereas, the levels were considerably
high in db/db mice (362638 mg/dl). These results suggested
VEGF-A expression levels and islet vascularity may correlate with
the compensatory efficiency of b cell hyperplasia. It is of great
importance to clarify the physiological relevance of FoxO1 in the
regulation of islet vasculature and compensatory b cell hyperplasia
in future studies.
Discussion
In a series of our previous study, we hypothesized that FoxO1 is
a negative regulator of b cell proliferation and neogenesis [10,15].
On the other hand, it has been known that in type2 diabetes, b cell
failure is caused by the insulin resistance in b cell per se [1,2,3,4].
In the state of insulin resistance, FoxO1 should be dephosphor-
ylated and activated in b cells. In this study we investigated TG
mice expressing active FoxO1 specifically in pancreas and showed
that TG mice exhibit hyperglycemia. This report provide in vivo
evidence that dysregulation of FoxO1 in pancreas causes
decreased b cell mass and impaired insulin secretion, leading to
the development of diabetes. Our finding that Pdx1 expression is
decreased in b cells of TG mice (Fig. 2C) is consistent with our
previous hypothesis that FoxO1 inhibits Pdx1 transcription [10].
However, the decrease of MafA expression in b cells of TG mice
(Fig. 2D) is inconsistent with our previous hypothesis that FoxO1
induces MafA expression and protects b cells against oxidative
stress [21]. The decrease in MafA expression may be accounted
for by the reduction of Pdx1, which is a master regulator of MafA
transcription.
Another conclusion in our previous study was that FoxO1
regulates cellular differentiation cooperatively with Notch signal-
ing [16]. Consistent with this conclusion, the phenotype of
pancreatic morphology in TG mice includes essentially the same
abnormalities of pancreas development seen in pancreas specific,
constitutively active Notch1 knockin mice, i.e. decrease in exocrine
acini, disruption of islet composition, and enlarged pancreatic
ducts [17]. The metabolic phenotype could not been analyzed in
Notch1 knockin mice because of perinatal lethality. In contrast, we
analyzed the metabolic phenotype in adult TG mice and showed
TG mice have impaired glucose tolerance and some develop overt
diabetes (Fig. 1).
We previously generated the transgenic mice expressing a
constitutively active FoxO1 driven by the Ttr promoter (line 305)
[26], in which constitutively active FoxO1 is expressed in both
liver and pancreatic b cells. Line 305 mice developed diabetes due
to increased hepatic glucose production and impaired b cell
compensation. The difference between line 305 mice and the TG
mice in the present study is that the former exhibited insufficient b
cell compensation against hepatic insulin resistance, by contrast,
the latter showed significantly impaired insulin secretion and
decreased b cell mass.
Despite that b cell mass was reduced in both male and female
TG mice, impairment of glucose tolerance was much milder in
female TG mice than male TG mice (Fig. 1). Glucose responsive
insulin secretion was also impaired in only male, not female, TG
mice (Fig. 1B). We speculate that sex hormones may differentially
regulate FoxO1 activation or differentially affect b cell function
between male and female TG mice; further studies will be needed
to elucidate this. It is also of interest that there was a wide variation
in blood glucose levels in male TG mice (Fig. 1A and 1G).
Therefore, we tested whether the blood glucose level correlates
with Pdx1 and/or FoxO1 expression level in TG mice. The results
indicated there was a trend for negative correlation between Pdx1
and blood glucose level (R=20.37) without statistic significance
(P=0.41) and no correlation between FoxO1 and hyperglycemia
(data not shown). Thus, we still don’t know the reason for a wide
variation in blood glucose levels in TG mice. Although there is no
statistic significance (P value is 0.08 by ANOVA), the absolute
number of a cells tends to be increased (Fig. 2B). These results are
consistent with our previous observation that overexression of
FoxO1-ADA leads to the differentiation of pancreatic duct cells
into a cells [15]. Furthermore, the higher levels of plasma
glucagon in TG mice than control mice (Fig. 1E) are likely
accounted by the increased a cell number. Although plasma
glucagon levels should be logically decreased after feeding, our
results demonstrated that plasma glucagon levels were increased in
the fed state compared to the fasted state in both TG and control
mice (Fig. 1E). This may be due to the difference of the nutrient
composition of chow diet (60% carbohydrate, 15% fat and 25%
protein) used in this study. It is notable that similar observation
(increasing plasma glucagon after feeding) has been reported by
other group [27].
Figure 6. Islet vascularity and VEGF-A expression in HFHSD fed
mice and db/db mice. (A) Immunohistochemistry with anti-PECAM1
or anti-VEGF-A antibodies in pancreatic sections from HFHSD fed mice,
db/db, and control mice. Six male mice from each genotype and six
sections per mouse were analyzed. Representative images are shown.
(B) Islets were isolated from HFHSD fed mice, db/db, and control mice
and used for analyses by real-time RT-PCR to quantify PECAM1 and
VEGF-A mRNA levels. Six male mice were analyzed for each genotype.
The results were normalized using GAPDH. Data represent the mean 6
SEM fold-increase relative to control mice. An asterisk indicates P,0.05
by ANOVA.
doi:10.1371/journal.pone.0032249.g006
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progenitor for b cells [28]. However, all duct cells are not
progenitors, but only a few duct cells develop to new islets. On the
other hand, we previously reported that FoxO1 essentially inhibits
b cell neogenesis from duct cells, as the loss of FoxO1 in pancreatic
duct cells enhanced b cell neogenesis [15]. Therefore, FoxO1
overexpression in pancreatic duct cells increases duct cell
proliferation, which leads to pancreatic cyst formation, but at
the same time it also inhibits b cell neogenesis from duct
progenitors, resulting in the loss of b cells and hyperglycemia.
Cystic disease of the pancreas is classified into two groups,
pancreatic cyst and pseudocyst [29]. Pancreatic pseudocysts often
follow chronic or acute pancreatitis or blunt trauma to the
abdomen. On the other hand, the cause of pancreatic cysts is
unknown, except for rare genetic disorders, such as von Hippel-
Lindau Disease [30]. There is no report indicating the relevance
between FoxO1 and human pancreatic cystic disease, and also no
mechanistic implications for FoxO1 regulating pancreatic cyst
formation. As we previously reported [10], there are a few Pdx1-
positive ductal cells in the adult pancreas. FoxO1-ADA expression
in those ductal cells can be speculated to cause cyst formation in
the pancreas of TG mice. Therefore, more precise analyses of
pancreatic cysts in TG mice may provide novel mechanistic
implications for the etiology of these cysts. Furthermore, the
association between pancreatic cystic disease and diabetes hasn’t
been reported. Therefore, it is intriguing that FoxO1 dysregulation
in pancreatic cells causes both diabetes and pancreatic polycysts in
TG mice. Further investigation will be needed to clarify the
association of diabetes and pancreatic cystic disease.
Genetic studies have revealed that islet vascular formation,
which is regulated by VEGF-A expression in b cells, is important
for the control of blood glucose levels [23,24,25]. In this study, we
showed FoxO1 regulates VEGF-A expression in b cells and
thereby increases capillaries in islets. FoxO1 regulation of VEGF-
A/islet vascular formation may contribute to compensatory b cell
hyperplasia against peripheral insulin resistance, a hallmark of
type 2 diabetes. It seems contradictory that FoxO1 increases islet
vascularities while decreasing the number of b cells. However,
FoxO1 may function as a double-edged sword, e.g. we previously
reported that FoxO1 protects against b cell failure under oxidative
stress [21], despite that FoxO1 has been known to inhibit b cell
proliferation and neogenesis [10,15]. Alternative explanation is
that FoxO1 overexpression in pancreas indeed reduces b cells and
causes hyperglycemia in TG mice, but at the same time FoxO1
increases islet vascularities, which could account for the milder
reduction of insulin secretion (Fig. 1E) and the milder glucose
intolerance (Fig. 1C), in spite of the severe reduction of b cells
(Fig. 2A and 2B).
Very recently Tsunekawa et al. reported that FoxO3a but not
FoxO1 regulates IRS2 gene transcription in b cells, despite that
both FoxO3a and FoxO1 were capable to bind to the IRS2
promoter [22]. In the present study, we showed only FoxO1, not
FoxO3a, recruits to the VEGF-A promoter, providing important
implications for target specificity between FoxO1 and FoxO3a in
b cells. Therefore, it is intriguing to test in future study how FoxO1
and FoxO3a share a role in the regulation of b cell growth and
function.
Although both animal models had peripheral insulin resistance,
HFHSD fed mice were resistant to developing hyperglycemia due
to effective compensatory b cell hyperplasia, which is associated
with increased VEGF-A expression and islet vasculature; whereas,
db/db mice developed severe diabetes due to insufficient b cell
hyperplasia which is accounted for by unchanged or decreased
VEGF-A expression and islet vasculature (Fig. 6). In db/db mice, it
is still unclear whether the lack of leptin signaling correlates with
the decreased VEGF-A expression [31]. Furthermore, it remains
unknown whether FoxO1 levels in the pancreas are relevant to the
difference in these two animal models. Future studies will clarify
the physiological relevance between FoxO1 and compensatory b
cell hyperplasia against insulin resistance.
In conclusion, we demonstrated that FoxO1 gain of function in
the pancreas causes diabetes, polycystic pancreas, and islet
hypervascularization. We propose that dysregulation of FoxO1
activity in the pancreas may account for the development of
diabetes and pancreatic cysts.
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